SCHEMBL4675321

SCHEMBL4675321

O=C(C=C(O)c1nc[nH]n1)c1cc(-c2ccccc2)oc1CCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
FAAH O00519 4/20 0.36
NR3C2 P08235 1/20 0.34
CES1 P23141 1/20 0.34
PKM P14618 2/20 0.33
HTT P42858 2/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KLKB1 P03952 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SLC16A3 O15427 1/20 0.32
FFAR1 O14842 1/20 0.32
PDE4A P27815 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5899397 0.84 FAAH (0.36) ALDH1A1KDM4EFAAHNR3C2CES1
SCHEMBL4672626 0.82 BRS3 (0.33) FAAHNR3C2CES1PPARGPPARA
SCHEMBL4674759 0.82 NR3C2 (0.36) KDM4ENR3C2
SCHEMBL4672261 0.82 GPR52 (0.32) NR3C2FFAR1AURKA
SCHEMBL4670631 0.82 NR3C2 (0.34) ALDH1A1KDM4EFAAHNR3C2CES1
SCHEMBL5899347 0.81 PARP1 (0.36) ALDH1A1KDM4ENR3C2LMNAL3MBTL1
SCHEMBL4678674 0.78 GPR52 (0.35) ALDH1A1FAAHL3MBTL1FFAR1AURKA
SCHEMBL4670692 0.78 NR3C2 (0.33) FAAHNR3C2CES1L3MBTL1
SCHEMBL4675307 0.78 HPGD (0.46) ALDH1A1PKMHTTHSD17B10LMNA
SCHEMBL4672722 0.78 NR3C2 (0.36) KDM4ENR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885KDM4E 947/4885FAAH 2547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.